

Bernard Combe

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9097137/bernard-combe-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

282
papers

27,064
citations

69
h-index

163
g-index

317
ext. papers

31,764
ext. citations

4.1
avg, IF

6.32
L-index

#	Paper	IF	Citations
282	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825
281	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
280	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	7.4	1649
279	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	3.4	1487
278	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 631-7	2.4	1300
277	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 964-75	2.4	1210
276	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
275	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 573-86		520
274	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
273	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 34-45	2.4	508
272	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008 , 50, 2319-29		458
271	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2008 , 10, R30	5.7	308
270	Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 120-6	2.4	307
269	Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2807-16		294
268	Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 913-20	2.4	287
267	Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2458-66		280
266	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 948-959	2.4	243

265	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1629-35	2.4	222
264	Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2625-32		211
263	Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1736-43		211
262	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018 , 391, 2513-2524	4.0	199
261	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
260	Effect of methotrexate, anti-tumor necrosis factor β and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Arthritis Care and Research</i> , 2014 , 66, 1016-26	4.7	173
259	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 638-643	2.4	168
258	Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. <i>Annals of the Rheumatic Diseases</i> , 1999 , 58, 220-5	2.4	168
257	The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. <i>Joint Bone Spine</i> , 2011 , 78, 598-603	2.9	165
256	Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the Autoimmune and Rituximab registry. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1026-31	2.4	160
255	Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. <i>Clinical and Experimental Immunology</i> , 1985 , 59, 520-8	6.2	142
254	Sustained remission with etanercept tapering in early rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2014 , 371, 1781-92	59.2	141
253	Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 262-6	2.4	141
252	The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. <i>Joint Bone Spine</i> , 2007 , 74, 440-5	2.9	139
251	Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2642-51		135
250	Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. <i>Rheumatology</i> , 2011 , 50, 222-9	3.9	134
249	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 851-858	2.4	133
248	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. <i>Journal of Biological Chemistry</i> , 2005 , 280, 15709-18	5.4	126

247	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 491-496	2.4	125
246	A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years. <i>Joint Bone Spine</i> , 2009 , 76, 654-7	2.9	119
245	Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 862-8	2.4	118
244	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 98-103	2.4	117
243	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1589-95	2.4	117
242	Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 887-91	2.4	109
241	Bone mineral density of 704 amateur sportsmen involved in different physical activities. <i>Osteoporosis International</i> , 2001 , 12, 152-7	5.3	107
240	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet, The</i> , 2016 , 388, 2763-2774	4.0	106
239	B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. <i>Arthritis and Rheumatism</i> , 2011 , 63, 933-8		106
238	Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006 , 73, 388-95	2.9	105
237	Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. <i>Arthritis and Rheumatism</i> , 2008 , 58, 88-97		104
236	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014 , 81, 287-97	2.9	100
235	Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1815-9	2.4	98
234	Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2037-46	9.5	97
233	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019 , 71, 599-611	9.5	96
232	Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 675-80	2.4	93
231	Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. <i>Journal of Rheumatology</i> , 1999 , 26, 7-13	4.1	88
230	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 482-92	2.4	87

229	Non-drug treatment (excluding surgery) in rheumatoid arthritis: clinical practice guidelines. <i>Joint Bone Spine</i> , 2009 , 76, 691-8	2.9	87
228	Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. <i>Arthritis Research and Therapy</i> , 2008 , 10, R106	5.7	87
227	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 479-81	2.4	85
226	Radiological damage in patients with rheumatoid arthritis on sustained remission. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 358-63	2.4	85
225	Tumor necrosis factor-alpha blockers in SAPHO syndrome. <i>Journal of Rheumatology</i> , 2010 , 37, 1699-704	4.1	84
224	Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1357-62	2.4	81
223	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e419-e426	14.2	81
222	Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. <i>Joint Bone Spine</i> , 2007 , 74, 638-46	2.9	78
221	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. <i>Joint Bone Spine</i> , 2015 , 82, 345-51	2.9	74
220	Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3692-701		73
219	Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. <i>Arthritis Care and Research</i> , 2010 , 62, 1787-95	4.7	72
218	Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. <i>Rheumatology</i> , 1996 , 35, 664-8	3.9	72
217	Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2003 , 30, 2344-9	4.1	70
216	Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2014 , 81, 215-21	2.9	69
215	Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 1998 , 57, 110-3	2.4	69
214	Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1999 , 58, 291-6	2.4	69
213	How to predict prognosis in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 137-46	5.3	68
212	Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). <i>Arthritis and Rheumatism</i> , 2011 , 63, 1804-11		67

211	Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 799-804	2.4	66
210	A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1430-5	2.4	65
209	Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006 , 73, 379-87	2.9	64
208	Combination etanercept and methotrexate provides better disease control in very early (4 months and . <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 989-92	2.4	63
207	Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1783-90	2.4	63
206	Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2006 , 8, R40	5.7	62
205	Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 1993 , 20, 1129-32	4.1	62
204	Early rheumatoid arthritis: strategies for prevention and management. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 27-42	5.3	59
203	Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2007 , 74, 627-37	2.9	59
202	Progression in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 59-69	5.3	57
201	Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. <i>Joint Bone Spine</i> , 2014 , 81, 6-14	2.9	56
200	Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2012 , 14, R249	5.7	56
199	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 694-700	2.4	55
198	Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2009 , 11, R114	5.7	55
197	Operational Definition of Active and Healthy Ageing (AHA): A Conceptual Framework. <i>Journal of Nutrition, Health and Aging</i> , 2015 , 19, 955-60	5.2	54
196	Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). <i>Rheumatology</i> , 2009 , 48, 425-32	3.9	54
195	Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease. <i>Arthritis and Rheumatism</i> , 1993 , 36, 608-12		54
194	Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. <i>Rheumatology</i> , 1995 , 34, 529-34	3.9	53

193	Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort. <i>Arthritis Care and Research</i> , 2015 , 67, 905-12	4.7	52
192	Update of French society for rheumatology recommendations for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2019 , 86, 135-150	2.9	52
191	Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. <i>Rheumatology</i> , 2015 , 54, 915-26	3.9	49
190	Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. <i>Journal of Rheumatology</i> , 2001 , 28, 173-81	4.1	49
189	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. <i>BMJ, The</i> , 2019 , 364, l67	5.9	48
188	Rheumatoid arthritis after Chikungunya fever: a prospective follow-up study of 21 cases. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1505-6	2.4	48
187	Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006 , 73, 396-402	2.9	48
186	Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. <i>Journal of Rheumatology</i> , 1991 , 18, 1323-7	4.1	47
185	Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. <i>Osteoporosis International</i> , 2018 , 29, 2389-2397	5.3	45
184	A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells. <i>Journal of Autoimmunity</i> , 2016 , 73, 64-72	15.5	43
183	The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005 , 23, 795-800	2.2	43
182	Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 724-9	2.4	42
181	Understanding emerging treatment paradigms in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011 , 13 Suppl 1, S3	5.7	42
180	Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 386-9	2.4	42
179	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2094-100	2.4	38
178	Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. <i>Journal of Rheumatology</i> , 2011 , 38, 990-6	4.1	38
177	Glucocorticoids in rheumatoid arthritis: current status and future studies. <i>RMD Open</i> , 2020 , 6,	5.9	37
176	Arthritis after infection with Chikungunya virus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011 , 25, 337-46	5.3	37

175	Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005 , 72, 222-8	2.9	37
174	Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. <i>Joint Bone Spine</i> , 2014 , 81, 352-9	2.9	36
173	Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017 , 3, e000404	5.9	35
172	Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1251-6	2.4	35
171	Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2006 , 73, 433-41	2.9	35
170	Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. <i>Rheumatology</i> , 2016 , 55, 874-82	3.9	34
169	Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. <i>Rheumatology</i> , 2017 , 56, 1746-1754	3.9	34
168	Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. <i>Journal of Rheumatology</i> , 2013 , 40, 1650-7	4.1	34
167	Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort. <i>Arthritis Care and Research</i> , 2013 , 65, 1899-906	4.7	33
166	Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR. <i>Joint Bone Spine</i> , 2015 , 82, 13-7.	2.9	32
165	High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. <i>Rheumatology</i> , 2015 , 54, 601-8	3.9	32
164	Rheumatoid nodulosis: report of two new cases and discussion of diagnostic criteria. <i>Journal of Rheumatology</i> , 1988 , 15, 1427-30	4.1	32
163	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 848-858	2.4	32
162	Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1797-1802	2.4	31
161	Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. <i>Rheumatology</i> , 2015 , 54, 520-7	3.9	28
160	First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort. <i>Arthritis Care and Research</i> , 2013 , 65, 1907-15	4.7	28
159	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 967-975	5.3	28
158	Chikungunya Virus-Associated Disease. <i>Current Rheumatology Reports</i> , 2017 , 19, 69	4.9	27

157	Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. <i>Rheumatology</i> , 2015 , 54, 748-50	3.9	27
156	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
155	Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1683-6	2.4	27
154	Ability of oblique foot radiographs to detect erosions in early arthritis: results in the ESPOIR cohort. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1729-34		27
153	Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. <i>Rheumatology</i> , 2010 , 49, 147-55	3.9	26
152	Polymorphism of the HLA-DMA and DMB genes in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 854-8		26
151	Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005 , 72, 229-34	2.9	26
150	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	26
149	Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2018 , 85, 15-22	2.9	24
148	Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. <i>Arthritis Care and Research</i> , 2014 , 66, 1289-95	4.7	24
147	TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. <i>Joint Bone Spine</i> , 2006 , 73, 547-53	2.9	24
146	Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2012 , 14, R156	5.7	23
145	Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1803-6	2.4	23
144	Should patients with recent-onset polyarthritis receive aggressive treatment?. <i>Joint Bone Spine</i> , 2004 , 71, 475-80	2.9	23
143	Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017 , 3, e000406	5.9	22
142	Rheumatoid arthritis of the hand: monitoring with a simplified MR imaging scoring method--preliminary assessment. <i>Radiology</i> , 2010 , 256, 863-9	20.5	22
141	Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. <i>Journal of Rheumatology</i> , 2013 , 40, 386-93	4.1	20
140	Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. <i>Journal of Rheumatology</i> , 2016 , 43, 1285-91	4.1	20

139	Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. <i>Journal of Rheumatology</i> , 2016 , 43, 1063-7	4.1	20
138	Targeting the Fas/FasL system in Rheumatoid Arthritis therapy: Promising or risky?. <i>Cytokine</i> , 2015 , 75, 228-33	4	19
137	Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009 , 76, 532-9	2.9	19
136	Improvement of fatigue in patients with rheumatoid arthritis treated with biologics: relationship with sleep disorders, depression and clinical efficacy. A prospective, multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 85-92	2.2	19
135	Relative clinical influence of clinical, laboratory, and radiological investigations in early arthritis on the diagnosis of rheumatoid arthritis. Data from the French Early Arthritis Cohort ESPOIR. <i>Journal of Rheumatology</i> , 2010 , 37, 2486-92	4.1	18
134	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 14	5.7	17
133	Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohort. <i>Joint Bone Spine</i> , 2014 , 81, 409-15	2.9	17
132	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1477-86	2.4	17
131	Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 904-13		17
130	Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences. <i>Arthritis and Rheumatism</i> , 2009 , 61, 425-34		17
129	Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007 , 74, 330-7	2.9	17
128	Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2054-2060	2.4	16
127	Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e19	2.4	16
126	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016 , 55, 1466-76	3.9	16
125	Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2019 , 86, 49-54	2.9	16
124	Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phase. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 590-5	2.4	15
123	Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy. <i>Joint Bone Spine</i> , 2007 , 74, 73-8	2.9	15
122	The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort. <i>Rheumatology</i> , 2015 , 54, 2166-70	3.9	14

121	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. <i>RMD Open</i> , 2015 , 1, e000037	5.9	14
120	Potential classification criteria for rheumatoid arthritis after two years: results from a French multicenter cohort. <i>Arthritis Care and Research</i> , 2013 , 65, 1227-34	4.7	14
119	Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007 , 74, 338-45	2.9	14
118	Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007 , 74, 346-52	2.9	14
117	Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2019 , 21, 140	5.7	13
116	The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. <i>Cytokine</i> , 2013 , 63, 81-90	4	13
115	Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009 , 76, 524-31	2.9	13
114	Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. <i>RMD Open</i> , 2016 , 2, e000245	5.9	12
113	Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 1614-22	4.1	12
112	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. <i>RMD Open</i> , 2015 , 1, e000128	5.9	12
111	Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort. <i>Rheumatology</i> , 2012 , 51, 1648-54	3.9	12
110	A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 1056-1060	2.2	12
109	Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 41-6	4.1	11
108	Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study. <i>Clinical and Experimental Rheumatology</i> , 2009 , 27, 84-91	2.2	11
107	GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. <i>Rheumatology</i> , 2013 , 52, 1890-7	3.9	10
106	Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 296-302	2.2	10
105	Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 658-667	2.2	10
104	Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1135-1138	2.4	9

103	Factors associated with a bad functional prognosis in early inflammatory back pain: results from the DESIR cohort. <i>RMD Open</i> , 2016 , 2, e000204	5.9	9
102	Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD. <i>Journal of Rheumatology</i> , 2017 , 44, 844-849	4.1	8
101	SPP1 rs9138 variant contributes to the severity of radiological damage in anti-citrullinated protein autoantibody-negative rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1840-3	2.4	8
100	Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2009 , 76, 540-6	2.9	8
99	Update on the use of etanercept across a spectrum of rheumatoid disorders. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 165-73	4.4	8
98	The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing. <i>Translational Medicine @ UniSa</i> , 2019 , 19, 66-81	0.5	8
97	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 85-99	5.1	8
96	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Oencia in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017 , 56, 629-637	3.9	7
95	Association Between Vitamin D Deficiency and Disease Activity, Disability, and Radiographic Progression in Early Rheumatoid Arthritis: The ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2020 , 47, 1624-1628	4.1	7
94	Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Française)</i> , 2014 , 81, 303-312	0.1	7
93	Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry. <i>RMD Open</i> , 2017 , 3, e000515	5.9	7
92	The French early arthritis registry. <i>Clinical and Experimental Rheumatology</i> , 2003 , 21, S123-8	2.2	7
91	TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 337-343	2.2	7
90	Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2015 , 17, 193	5.7	6
89	Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study. <i>Joint Bone Spine</i> , 2018 , 85, 461-468	2.9	6
88	Clinical association of mixed connective tissue disease and granulomatosis with polyangiitis: a case report and systematic screening of anti-U1RNP and anti-PR3 auto-antibody double positivity in ten European hospitals. <i>Immunologic Research</i> , 2016 , 64, 1243-1246	4.3	6
87	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021 , 23, 119	5.7	6
86	Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 3738-3746	3.9	6

85	Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). <i>Rheumatology</i> , 2021 , 60, 888-895	3.9	6
84	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 701-708	5.3	5
83	Polyarthrite rhumatoïde : clinique et diagnostic. <i>EMC - Appareil Locomoteur</i> , 2007 , 2, 1-15		5
82	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020 , 59, 1842-1852	3.9	5
81	Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2019 , 21, 243	5.7	5
80	Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. <i>Arthritis Research and Therapy</i> , 2021 , 23, 41	5.7	5
79	Predictors of fatigue and persistent fatigue in early rheumatoid arthritis: a longitudinal observational study, data from the ESPOIR cohort. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 259-266	1.9	4
78	Value of high-sensitivity C-reactive protein for classification of early axial spondyloarthritis: results from the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 785-6	2.4	4
77	THU0192 5-Year Results from the Rapid 1 Trial and Open-Label Extension: Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A228.2-A229	2.4	4
76	Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2009 , 11, R157	5.7	4
75	Recommandations de la Société française de rhumatologie pour l'utilisation des agents anti-TNF α chez les personnes souffrant de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007 , 74, 1301-1311	0.1	4
74	Immunopathologie de la polyarthrite rhumatoïde. <i>EMC - Rhumatologie-Orthopedie</i> , 2004 , 1, 218-230		4
73	Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e332-e338	14.2	4
72	Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. <i>RMD Open</i> , 2020 , 6,	5.9	4
71	The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis - methodology and baseline characteristics of the population. <i>Joint Bone Spine</i> , 2021 , 88, 105171	2.9	4
70	Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2017 , 44, 773-779	4.1	3
69	Diabetes at the time of rheumatoid arthritis diagnosis is an independent predictor of pejorative outcomes: Data from the early arthritis ESPOIR cohort. <i>Joint Bone Spine</i> , 2018 , 85, 773-775	2.9	3
68	Les nouveaux critères de classification ACR/EULAR 2010 pour un diagnostic plus précoce de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme Monographies</i> , 2017 , 84, 337-342	0	3

67	La cohorte Espoir: un suivi de dix ans des arthrites débutantes en France. Méthodologie et caractéristiques initiales des 813 patients inclus. <i>Revue Du Rhumatisme (Edition Française)</i> , 2007 , 74, 838-844	0.1	3
66	Regression of an expanded subpopulation of large granular lymphocytes in a patient with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1991 , 34, 246-7		3
65	Low Influenza, Pneumococcal and Diphtheria-Tetanus-Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren's Syndrome: A Cross-Sectional Study. <i>Vaccines</i> , 2019 , 8,	5.3	3
64	Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. <i>Rheumatology</i> , 2021 , 60, 5073-5079	3.9	3
63	Risk of Diverticulitis and Gastrointestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab or Abatacept. <i>Rheumatology</i> , 2021 ,	3.9	3
62	Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2020 , 22, 13	5.7	2
61	SAT0084 Effects of different steroid doses on adverse events and radiographic progression of certolizumab pegol-treated rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 498.2-498	2.4	2
60	THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A221.4-A222	2.4	2
59	FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry Ebactemra). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A456.3-A457	2.4	2
58	FRI0173 Gastrointestinal perforations with certolizumab PEGOL. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 370.2-370	2.4	2
57	Progrès dans la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Française)</i> , 2007 , 74, 14-21	0.1	2
56	L'évaluation clinique et biologique dans la prise en charge de personnes souffrant de polyarthrite rhumatoïde établissement de recommandations pour la pratique clinique à partir de données de la littérature et d'opinions d'experts (Rencontres d'experts en rhumatologie). <i>Revue Du Rhumatisme (Edition Française)</i> , 2004 , 71, 8107-8126	0.1	2
55	Enquête naturaliste sur l'utilisation des anti-inflammatoires non stéroïdiens chez des patients souffrant de douleurs rhumatologiques. <i>Revue Du Rhumatisme (Edition Française)</i> , 2003 , 70, 416-423	0.1	2
54	Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR. <i>Joint Bone Spine</i> , 2021 , 88, 105060	2.9	2
53	Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). <i>Rheumatology and Therapy</i> , 2021 , 8, 199-217	4.4	2
52	Cytomegalovirus infection: friend or foe in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2021 , 23, 16	5.7	2
51	Les nouveaux critères ACR/EULAR de classification de la polyarthrite rhumatoïde. Implications pour la pratique. <i>Revue Du Rhumatisme (Edition Française)</i> , 2011 , 78, 497-499	0.1	1
50	Diagnostic du rhumatisme psoriasique de forme périphérique : élaboration de recommandations pour la pratique clinique, à partir d'une analyse systématique de la littérature et de l'opinion d'experts: Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on data from the literature and experts opinion. <i>Revue Du Rhumatisme (Edition Française)</i> , 2007 , 74, 15-22	0.1	1

49	Polyarthrite rhumatoïde de l'adulte : traitement. <i>EMC - Appareil Locomoteur</i> , 2006 , 1, 1-23		1
48	The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 11	5.7	1
47	Response to: 'Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk' by Pareek. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e22	2.4	1
46	Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. <i>Clinical Rheumatology</i> , 2021 , 40, 4943-4954	3.9	1
45	ESPOIR and the French database management: what have we learned from the first years of follow-up?. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, S-153-7	2.2	1
44	Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 501-507	2.2	1
43	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. <i>RMD Open</i> , 2021 , 7, e001698	5.9	1
42	Artritis reumatoide: clínica y diagnóstico. <i>EMC - Aparato Locomotor</i> , 2007 , 40, 1-17	0	0
41	Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohort. <i>Rheumatology</i> , 2021 , 60, 1863-1870	3.9	0
40	Disease-modifying drug retention rate according to patient age in patients with early rheumatoid arthritis: analysis of the ESPOIR cohort. <i>Rheumatology International</i> , 2021 , 41, 879-885	3.6	0
39	Comparison of modified disease-activity scores with original composite scores for prediction of structural damages in rheumatoid arthritis: Data from the ESPOIR cohort. <i>Joint Bone Spine</i> , 2017 , 84, 111-112	2.9	
38	Présentation clinique des patients souffrant de rachialgie inflammatoire chronique récente (patronne de spondyloarthrite) : la cohorte Desir. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015 , 82, 378-385	0.1	
37	Comparaison de scores modifiés d'activité avec les scores composites originaux pour la prédiction des dommages structuraux dans la polyarthrite rhumatoïde : les données de la cohorte ESPOIR. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018 , 85, 100-101	0.1	
36	Artritis reumatoide del adulto: estrategias terapéuticas. <i>EMC - Aparato Locomotor</i> , 2016 , 49, 1-24	0	
35	FRI0219 Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in The French Registry Regate (Registry Roactemra). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 511.2-511	2.4	
34	La présence de diabète lors du diagnostic de la polyarthrite rhumatoïde est un facteur indépendant prédictif de mauvais résultats : données de la cohorte ESPOIR sur les polyarthrites récentes. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019 , 86, 534-536	0.1	
33	Taux de rétention de l'adalimumab, de l'etanercept et de l'infliximab en 1re ou 2e ligne de biothérapie chez les patients atteints de polyarthrite rhumatoïde en pratique courante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014 , 81, 483-490	0.1	
32	Reply to Talarico et al.'s comment: "Rate of serious infections in patients with rheumatoid arthritis receiving tumor necrosis factor (TNF)-alpha antagonist: a prospective observational study". <i>Joint Bone Spine</i> , 2014 , 81, 379-80	2.9	

31	AB0438 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis WHO HAD an Inadequate Response to Tnf-Alpha Inhibitors: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study. <i>Annals of the Rheumatic Diseases</i> , 2014 , <i>73</i> , 952-953	2.4
30	THU0485 The SPP1 Rs9138 Variant Contributes to the Severity of Radiologic Damage in Acpa-Negative Rheumatoid Arthritis: Results from the ESPOIR and Leiden EAC Cohorts. <i>Annals of the Rheumatic Diseases</i> , 2014 , <i>73</i> , 351.1-351	2.4
29	SAT0048 Identification of Genes Regulating Trail-Induced Apoptosis in Rheumatoid Arthritis Fibroblasts-Like Synoviocytes (RA FLS). <i>Annals of the Rheumatic Diseases</i> , 2015 , <i>74</i> , 665.2-665	2.4
28	Artritis reumatoide del adulto: epidemiolog�a, cl�nica y diagn�stico. <i>EMC - Aparato Locomotor</i> , 2015 , <i>48</i> , 1-17	0
27	Pr�valence et concordance de la r�mission pr�coce et prolong�e valu�e par diff�rents indices valid�s de la cohorte d'arthrites d�butantes « ESPOIR ». <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015 , <i>82</i> , 47-53	0.1
26	THU0264 In Early Rheumatoid Arthritis (Espoir Cohort), Serum CCL19 Level is Associated with Disease Activity, Autoantibody Secretion and 3-Year Radiographic Progression: Data from the Espoir Cohort. <i>Annals of the Rheumatic Diseases</i> , 2014 , <i>73</i> , 274.2-274	2.4
25	FRI0048 Prevalence of Tuberculosis in Early Arthritis and Early Spondyloarthritis Increased in Comparison to the General Population - Results from the ESPOIR and DESIR Cohorts. <i>Annals of the Rheumatic Diseases</i> , 2014 , <i>73</i> , 398.2-399	2.4
24	Que nous ont apport�es les premi�res ann�es d'�tudes d'une cohorte de polyarthrites rhumato�ides d�butantes : la cohorte ESPOIR?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014 , <i>81</i> , 455-459	0.1
23	Crit�res composites de suivi d'activit� dans la polyarthrite rhumato�ide. <i>Revue Du Rhumatisme Monographies</i> , 2010 , <i>77</i> , 17-21	0
22	Pronostic et suivi du rhumatisme psoriasique de forme p�riph�rique : laboration de recommandations pour la pratique clinique, � partir d'une analyse syst�matique de la litt�rature et de l'opinion d'experts. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007 , <i>74</i> , 23-30	0.1
21	Les traitements m�dicamenteux (hors bioth�rapie) dans la prise en charge de patients atteints de rhumatisme psoriasique p�riph�rique : laboration de recommandations pour la pratique clinique, � partir d'une analyse syst�matique de la litt�rature et de l'opinion d'experts: Pharmacological	0.1
20	Arbre d'cisionnel permettant le choix en pratique clinique d'un traitement de fond de seconde intention au cours de la polyarthrite rhumato�ide r�cente, apr�s chec d'un traitement de fond de premi�re intention d'une dur�e de six mois. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007 , <i>74</i> , 79-84	0.1
19	Int�r�t du leflunomide en association aux traitements de fond traditionnels ou aux bioth�rapies dans la polyarthrite rhumato�ide. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2006 , <i>73</i> , 1283-1286	0.1
18	Artritis reumatoide del adulto: tratamiento. <i>EMC - Aparato Locomotor</i> , 2006 , <i>39</i> , 1-26	0
17	Faut-il traiter de fa�on agressive une polyarthrite d�butante ?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2004 , <i>71</i> , 854-859	0.1
16	Immunopatolog�a de la artritis reumatoide. <i>EMC - Aparato Locomotor</i> , 2004 , <i>37</i> , 1-9	0
15	Impact of multimorbidity on disease modifying anti-rheumatic drug therapy in early rheumatoid arthritis: data from the Espoir cohort.. <i>Joint Bone Spine</i> , 2021 , <i>89</i> , 105326	2.9
14	THU0207 SUSTAINABILITY OF RESPONSE TO UPADACITINIB AS MONOTHERAPY OR IN COMBINATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS. <i>Annals of the Rheumatic Diseases</i> , 2020 , <i>79</i> , 327.1-328	2.4

13	FRI0131 SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 647.1-648	2.4
12	L'apport et les indications des biothérapies dans les rhumatismes inflammatoires. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2012 , 196, 1279-1293	0.1
11	Pas de bénéfice des corticoïdes sur la progression radiologique et la rémission sans handicap ^ 10 ans : données de la cohorte ESPOIR. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020 , 87, A124-A125	0.1
10	OP0183 IDENTIFICATION OF A SUBGROUP OF PEOPLE WITH RHEUMATOID ARTHRITIS CHARACTERISED BY HIGH DISABILITY OVER 10 YEARS, DESPITE LOW INFLAMMATION: RESULTS FROM TWO EUROPEAN PROSPECTIVE COHORT STUDIES. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 110.2-111	2.4
9	POS0658 GEOGRAPHIC VARIATION OF EFFICACY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 570-571	2.4
8	POS0657 GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 569.2-570	2.4
7	POS0654 IMPACT OF CONCOMITANT GLUCOCORTICOIDS ON THE CLINICAL EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN AD HOC ANALYSIS OF DATA FROM THREE PHASE 3 STUDIES. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 567-568	2.4
6	L'association abatacept plus méthotrexate permet d'atteindre ^ nouveau la rémission, de manière efficace et bien tolérée, après reprise du traitement pour poussées inflammatoires chez des patients atteints de polyarthrite rhumatoïde précoce. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016 , 83, A43-A44	0.1
5	Response to: 'Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis' by Mathieu. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e66	2.4
4	Délai d'initiation d'une biothérapie dans la cohorte française ESPOIR. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021 , 88, 291-297	0.1
3	Impact of dosing on treatment with TNF inhibitors: managing dose adjustment. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S13-7	2.2
2	Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 242-252	2.2
1	Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 72	5.7